5,025 reports of this reaction
33.5% of all LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN reports
#1 most reported adverse reaction
GENERAL PHYSICAL HEALTH DETERIORATION is the #1 most commonly reported adverse reaction for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, manufactured by Novartis Pharmaceuticals Corporation. There are 5,025 FDA adverse event reports linking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN to GENERAL PHYSICAL HEALTH DETERIORATION. This represents approximately 33.5% of all 14,999 adverse event reports for this drug.
Patients taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN who experience general physical health deterioration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GENERAL PHYSICAL HEALTH DETERIORATION is a frequently reported adverse event for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, accounting for a significant proportion of all reports.
In addition to general physical health deterioration, the following adverse reactions have been reported for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN:
The following drugs have also been linked to general physical health deterioration in FDA adverse event reports:
GENERAL PHYSICAL HEALTH DETERIORATION has been reported as an adverse event in 5,025 FDA reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
GENERAL PHYSICAL HEALTH DETERIORATION accounts for approximately 33.5% of all adverse event reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, making it one of the most commonly reported side effect.
If you experience general physical health deterioration while taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.